Dell Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Dell Technologies Inc trades at $465.45 (market cap $284.93B), while Zimmer Biomet Holdings Inc trades at $95.73 (market cap $18.55B). The key difference: Dell Technologies Inc is far larger — about 15.4× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| DELL | ZBH | |
|---|---|---|
Market Cap | $284.93B | $18.55B |
Sector | Technology | Health |
52-Week High | $467.27 | $107.71 |
52-Week Low | $111.10 | $79.58 |
Enterprise Value | $304.51B | $25.61B |
Dividend Yield | 0.57% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.
The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →